{"quote": {"result": [{"language": "en-US", "region": "US", "quoteType": "EQUITY", "typeDisp": "Equity", "quoteSourceName": "Delayed Quote", "triggerable": false, "customPriceAlertConfidence": "LOW", "currency": "HKD", "firstTradeDateMilliseconds": 1623979800000, "priceHint": 3, "epsTrailingTwelveMonths": -1.85, "epsForward": -2.01, "epsCurrentYear": -1.77, "priceEpsCurrentYear": -6.5988703, "sharesOutstanding": 572625024, "bookValue": 4.319, "fiftyDayAverage": 13.56, "fiftyDayAverageChange": -1.8800001, "fiftyDayAverageChangePercent": -0.13864307, "twoHundredDayAverage": 14.9142, "twoHundredDayAverageChange": -3.2341995, "twoHundredDayAverageChangePercent": -0.21685371, "marketCap": 6688260608, "forwardPE": -5.8109455, "priceToBook": 2.70433, "sourceInterval": 15, "exchangeDataDelayedBy": 15, "ipoExpectedDate": "2021-06-10", "averageAnalystRating": "2.0 - Buy", "tradeable": false, "cryptoTradeable": false, "regularMarketChangePercent": -1.0169482, "regularMarketPrice": 11.68, "marketState": "CLOSED", "exchange": "HKG", "shortName": "CARSGEN-B", "longName": "CARsgen Therapeutics Holdings Limited", "messageBoardId": "finmb_713821465", "exchangeTimezoneName": "Asia/Hong_Kong", "exchangeTimezoneShortName": "HKT", "gmtOffSetMilliseconds": 28800000, "market": "hk_market", "esgPopulated": false, "regularMarketChange": -0.119999886, "regularMarketTime": 1683878916, "regularMarketDayHigh": 11.8, "regularMarketDayRange": "11.5 - 11.8", "regularMarketDayLow": 11.5, "regularMarketVolume": 894500, "regularMarketPreviousClose": 11.8, "bid": 11.66, "ask": 11.68, "fullExchangeName": "HKSE", "financialCurrency": "CNY", "regularMarketOpen": 11.8, "averageDailyVolume3Month": 2062036, "averageDailyVolume10Day": 971585, "fiftyTwoWeekLowChange": 2.4800005, "fiftyTwoWeekLowChangePercent": 0.26956528, "fiftyTwoWeekRange": "9.2 - 21.85", "fiftyTwoWeekHighChange": -10.17, "fiftyTwoWeekHighChangePercent": -0.46544623, "fiftyTwoWeekLow": 9.2, "fiftyTwoWeekHigh": 21.85, "earningsTimestamp": 1679396340, "earningsTimestampStart": 1679396340, "earningsTimestampEnd": 1679396340, "trailingAnnualDividendRate": 0.0, "trailingAnnualDividendYield": 0.0, "symbol": "2171.HK"}], "error": null}, "summary": {"result": [{"assetProfile": {"address1": "Building 12", "address2": "No. 388 Yindu Road Xuhui District", "city": "Shanghai", "country": "China", "website": "https://www.carsgen.com", "industry": "Biotechnology", "industryDisp": "Biotechnology", "sector": "Healthcare", "longBusinessSummary": "CARsgen Therapeutics Holdings Limited, an investment holding company, engages in discovering, developing, and commercializing chimeric antigen receptor T (CAR-T) cell therapies in China and the U.S. The company is developing autologous CAR-T product candidates, including CT053, which targets B-cell maturation antigen that is in pivotal Phase II/III trial for the treatment of relapsed/refractory multiple myeloma; CT041, which targets Claudin 18.2, is in Phase II/III clinical trial for gastric/gastroesophageal junction cancer and Phase I for pancreatic cancer, as well as in Phase I clinical trial for gastric or pancreatic cancer; and CT011, which is in Phase I clinical trial for patients with Glypican-3 positive advanced hepatocellular carcinoma. It is also developing CT032, which targets CD19 that is in Phase I/II clinical trial for the treatment of B cell non-Hodgkin's lymphoma; CT0180, which targets Glypican-3 that is in Phase I clinical trial for patients with Glypican-3 positive advanced hepatocellular carcinoma; and CT0181, which targets Glypican-3 that is in Phase I clinical trial for patients with Glypican-3 positive hepatocellular carcinoma. In addition, the company is developing CT0590, which targets B-cell maturation antigen that is in pre-clinical stage for the treatment of relapsed/refractory multiple myeloma; CT048, which targets Claudin 18.2 that is in pre-clinical stage for the treatment of gastric/gastroesophageal junction and pancreatic cancer; KJ-C2112, an epidermal growth factor receptor/variant III of epidermal growth factor receptor, which is in pre-clinical stage for the treatment of glioblastoma; and KJC2113 that targets mesothelin, as well as KJ-C2114 that are in pre-clinical stage for the treatment of solid tumors. Further, it is developing AB011, which is in Phase I clinical trial for the treatment of gastric/pancreatic cancer. The company was founded in 2014 and is headquartered in Shanghai, China.", "fullTimeEmployees": 539, "companyOfficers": [{"maxAge": 1, "name": "Dr. Zonghai  Li M.D., Ph.D.", "age": 47, "title": "Co-Founder, CEO, CSO & Chairman", "yearBorn": 1975, "exercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}, "unexercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}}, {"maxAge": 1, "name": "Dr. Huamao  Wang Ph.D.", "age": 45, "title": "Co-Founder, COO & Exec. Director", "yearBorn": 1977, "exercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}, "unexercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}}, {"maxAge": 1, "name": "Ms. Lan  Xie", "age": 49, "title": "Sr. VP of Fin.", "yearBorn": 1973, "exercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}, "unexercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}}, {"maxAge": 1, "name": "Dr. Hong  Ma", "age": 50, "title": "Sr. VP of Clinical Devel.", "yearBorn": 1972, "exercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}, "unexercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}}, {"maxAge": 1, "name": "Dr. Leigh  Hsu", "age": 51, "title": "Sr. VP of Bus. Devel.", "yearBorn": 1971, "exercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}, "unexercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}}, {"maxAge": 1, "name": "Ms. Caihua  Jiang", "title": "Sr. VP of Quality", "exercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}, "unexercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}}, {"maxAge": 1, "name": "Dr. Raffaele  Baffa M.D., Ph.D.", "age": 62, "title": "Chief Medical Officer", "yearBorn": 1960, "exercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}, "unexercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}}, {"maxAge": 1, "name": "Dr. Hua  Jiang", "age": 43, "title": "Exec. Director", "yearBorn": 1979, "exercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}, "unexercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}}, {"maxAge": 1, "name": "Dr. Sylvie  Peltier", "age": 59, "title": "Sr. VP of Global Regulatory Affairs", "yearBorn": 1963, "exercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}, "unexercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}}, {"maxAge": 1, "name": "Mr. Richard John  Daly M.B.A.", "age": 61, "title": "Pres of CARsgen Therapeutics Corp.", "yearBorn": 1961, "exercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}, "unexercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}}], "maxAge": 86400}}], "error": null}}